Abacavir sulfate/Dolutegravir sodium/Lamivudine

硫酸阿巴卡韦/多替拉韦钠/拉米夫定

Report date: 2026/03/18 11:15:10

Base Information

Drug NameAbacavir sulfate/Dolutegravir sodium/Lamivudine
Drug Alias Name多替阿巴拉米Lamivudine, abacavir and dolutegravirDolutegravir Sodium, Abacavir Sulfate and LamivudineDolutegravir-TriiDolutegravir Sodium/Abacavir Sulfate/Lamivudine +[13] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitorsHIV integrase inhibitors
TargetsHIV integraseReverse transcriptase
Therapy Area/IndicationsAmyotrophic Lateral SclerosisArthralgiaHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryUnited States
Original Approved Date2014/08/22
Country/TerritoryCanadaBotswanaUnited States +[18] 
CombinationsYes LamivudineDolutegravir SodiumAbacavir Sulfate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesViiv Healthcare
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcViiv Healthcare BvMylan Inc +[7] 
Inactive CompaniesMacquarie UniversityThe University Of Sydney - Brain And Mind Centre
Active IndicationsArthralgiaHIV Infections
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeJ05AR13
Related LinksWikipediaKEGG